Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans
Open accessThe DOI matches its Crossref record; 35 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Glucagon-like peptide (GLP)-1 lowers postprandial glycemia primarily through inhibition of gastric emptying. We addressed whether the GLP-1–induced deceleration of gastric emptying is subject to rapid tachyphylaxis and if so, how this would alter postprandial glucose control. RESEARCH DESIGN AND METHODS: Nine healthy volunteers (25 ± 4 years old, BMI: 24.6 ± 4.7 kg/m2) were examined with intravenous infusion of GLP-1 (0.8 pmol · kg−1 . min−1) or placebo over 8.5 h. Two liquid mixed meals were administered at a 4-h interval. Gastric emptying was determined, and blood samples were drawn frequently. RESULTS: GLP-1 decelerated gastric emptying significantly more after the first meal compared with the second meal (P = 0.01). This was associated with reductions in pancreatic polypeptide levels (marker of vagal activation) after the first but not the second meal (P < 0.05). With GLP-1, glucose concentrations declined after the first meal but increased after the second meal (P < 0.05). The GLP-1–induced reductions in postprandial insulin and C-peptide levels were stronger during the first meal course (P < 0.05). Likewise, glucagon levels were lowered by GLP-1 after the first meal but increased after the second test meal (P < 0.05). CONCLUSIONS: The GLP-1–induced delay in gastric emptying is subject to rapid tachyphylaxis at the level of vagal nervous activation. As a consequence, postprandial glucose control by GLP-1 is attenuated after its chronic administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Furthermore, GLP-1 can slow down gastric emptying by activating the vagus nerve, a part of the autonomic nervous system crucial for regulating the activities of the gastrointestinal tract.268”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [268]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 can slow down gastric emptying through its effects on smooth muscles and the nervous system in the gastrointestinal tract.264,268”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [268]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data also suggest that there is tachyphylaxis with prolonged use of GLP‐1 RAs [29, 60]”
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The magnitude of effect on GE, unlike the effects on glycaemic control or appetite, is attenuated with prolonged GLP-1 exposure.[2][3][4]”
From The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists (2020) · cites this paper as [3]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Native GIP mimicking postprandial GIP blood levels and GIPRAs did not reveal any relevant effects on GE. 3,[13][14][15]”
From The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists (2020) · cites this paper as [3]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“Although the glucose-lowering effect of GLP-1 in the fasting state is primarily mediated by its glucose-dependent augmentation of insulin secretion and inhibition of glucagon release (4,5), the key mechanism driving the postprandial normalization of glycemia by GLP-1 is a marked deceleration of gastric emptying leadin…”
BackgroundSelf-citationGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919 · cited 1×
“determined in ethanol-extracted plasma as previously described (15,18), using antiserum 89 390 for the measurement of intact GLP-1 [7–36 amide] plus cleavage products.”
MethodSelf-citationNauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817 · cited 2×
“fusion rate was based on previous studies (5,14) and was selected to increase”
BackgroundMethodSelf-citationTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670 · cited 1×
“A deceleration of gastric emptying by GLP-1 has been demonstrated in patients with type 2 diabetes and healthy individuals (5,8,14).”
BackgroundSelf-citationMitrakou, A., Kelley, D., Mokan, M., Veneman, T., Pangburn, T., Reilly, J., & Gerich, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201023260104 · Cited by 595 · cited 1×
“This is in contrast with previous studies showing a significant decline in glucagon levels after intravenous or oral glucose ingestion (31,32).”
ResultEnhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Nauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506 · cited 3×
“Given the importance of GIP as a physiologic incretin hormone (15,34), this might theoretically impair postprandial insulin responses and thus worsen glucose control.”
BackgroundMethodSelf-citationWillms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502
Self-citation
Cited by
Items 101–200 of 391
de Wit, H. M., Vervoort, G., Jansen, H. J., de Grauw, W. J. C., de Galan, B. E., & Tack, C. J. (2014) · Diabetologia · doi:10.1007/s00125-014-3302-0 · Cited by 75
“Glucagon-like peptide-1 (GLP-1) analogues stimulate insulin secretion, suppress glucagon release, and reduce food intake, resulting in improved glycaemic control and weight loss in type 2 diabetes [9–15].”
BackgroundJones, K. L., Rigda, R. S., Buttfield, M. D. M., Hatzinikolas, S., Pham, H. T., Marathe, C. S., Wu, T., Lange, K., Trahair, L. G., Rayner, C. K., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13633 · Cited by 66
“The latter appears to represent the major mechanism for lowering of postprandial glycaemia,(19,20) given that exogenous GLP-1 reduces, rather than increases, postprandial plasma insulin concentrations(19,20); however, the effect of exogenous GLP-1 to slow gastric emptying in healthy individuals is attenuated markedly…”
BackgroundThe Alpha-Cell as Target for Type 2 Diabetes Therapy
Christensen, M., Bagger, J. I., Vilsboll, T., & Knop, F. K. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.369 · Cited by 65
“Also, the slowing effect of GLP-1 on gastric emptying seems to decrease over time [86, 87].”
BackgroundBergmann, N. C., Lund, A., Gasbjerg, L. S., Jørgensen, N. R., Jessen, L., Hartmann, B., Holst, J. J., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00008 · Cited by 64
Self-citationSharma, A., & Verma, S. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.09.003 · Cited by 65
Give the Receptor a Brake: Slowing Gastric Emptying by GLP-1
Tong, J., & D’Alessio, D. (2014) · Diabetes · doi:10.2337/db13-1764 · Cited by 63
“Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.”
BackgroundResultInfluentialEffect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects
Keller, J., Trautmann, M. E., Haber, H., Tham, L. S., Hunt, T., Mace, K., & Linnebjerg, H. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2012.08.005 · Cited by 61
“It remains to be investigated whether there would be a reduction of the effect of exenatide on gallbladder motility over time with repeated administration of drug, as a decreased effect of exenatide on gastric emptying is observed over time [12].”
BackgroundGLP-1 based therapies: clinical implications for gastroenterologists
Smits, M. M., van Raalte, D. H., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., & Cahen, D. L. (2016) · Gut · doi:10.1136/gutjnl-2015-310572 · Cited by 61
Tharakan, G., Behary, P., Wewer Albrechtsen, N. J., Chahal, H., Kenkre, J., Miras, A. D., Ahmed, A. R., Holst, J. J., Bloom, S. R., & Tan, T. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0446 · Cited by 61
Self-citationGorgojo-Martínez, J. J., Feo-Ortega, G., & Serrano-Moreno, C. (2016) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.02.013 · Cited by 60
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Geloneze, B., de Lima-Júnior, J. C., & Velloso, L. A. (2017) · Drugs · doi:10.1007/s40265-017-0706-4 · Cited by 60
Guo, M., Gu, J., Teng, F., Chen, J., Ma, X., Chen, Q., Pu, Y., Jiang, Z., Long, Y., & Xu, Y. (2020) · Endocrine · doi:10.1007/s12020-019-02175-6 · Cited by 69
A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes
Furihata, K., Mimura, H., Urva, S., Oura, T., Ohwaki, K., & Imaoka, T. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14572 · Cited by 59
Xiao, C., Dash, S., Morgantini, C., Adeli, K., & Lewis, G. F. (2015) · Diabetes · doi:10.2337/db14-1706 · Cited by 60
“GLP-1 is well known to slow gastric emptying (44,45), which is expected to slow the passage of dietary fat to the small intestine.”
BackgroundZhang, F., Tong, Y., Su, N., Li, Y., Tang, L., Huang, L., & Tong, N. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12198 · Cited by 59
Guo, X., Zhou, Z., Lyu, X., Xu, H., Zhu, H., Pan, H., Wang, L., Yang, H., & Gong, F. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1844-1176 · Cited by 59
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
Crane, J., & McGowan, B. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315620180 · Cited by 59
“Indeed, the retardation of gastric emptying by GLP-1 is subject to a rapid tachyphylaxis in experimental studies [Nauck et al. 2011].”
BackgroundMechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes
Horowitz, M., Rayner, C. K., & Jones, K. L. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0009-4 · Cited by 58
Joshi, G. P. (2024) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000006810 · Cited by 57
Wu, T., Rayner, C. K., & Horowitz, M. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_9 · Cited by 68
Denney, W. S., Sonnenberg, G. E., Carvajal‐Gonzalez, S., Tuthill, T., & Jackson, V. M. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13127 · Cited by 57
“A similar comparison of vagal tachyphylaxis has been used to explain differences in efficacy with chronic dosing of injectable GLP-1 agonists [78-80].”
Measurement of gastric emptying in diabetes
Phillips, L. K., Rayner, C. K., Jones, K. L., & Horowitz, M. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.06.005 · Cited by 55
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes
Ahrén, B. (2014) · World J Diabetes · doi:10.4239/wjd.v5.i1.40 · Cited by 51
Nexøe‐Larsen, C. C., Sørensen, P. H., Hausner, H., Agersnap, M., Baekdal, M., Brønden, A., Gustafsson, L. N., Sonne, D. P., Vedtofte, L., Vilsbøll, T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13420 · Cited by 51
“tmax increased to 104 (21-240) minutes after the first liraglutide 0.”
BackgroundO’Connor‐Semmes, R., Lin, J., Hodge, R. J., Andrews, S. M., Chism, J. P., Choudhury, A., & Nunez, D. J. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.187 · Cited by 55
Rayner, C. K., Watson, L. E., Phillips, L. K., Lange, K., Bound, M. J., Grivell, J., Wu, T., Jones, K. L., Horowitz, M., Ferrannini, E., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0190 · Cited by 50
Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects
Becker, R. H. A., Stechl, J., Steinstraesser, A., Golor, G., & Pellissier, F. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2647 · Cited by 49
HOCKING, S. L., Scott, D. A., Remedios, M. L., Horowitz, M., Story, D., Greenfield, J. R., Boussioutas, A., Devereaux, B., Andrikopoulos, S., Shaw, J. E., et al. (2025) · Anaesthesia and Intensive Care · doi:10.1177/0310057x251355288 · Cited by 70
“17 Leading from this, assumptions have been made that the gastric motility effects of longer acting GLP-1RAs are reduced with prolonged dosing.”
Trahair, L. G., Horowitz, M., Stevens, J. E., Feinle‐Bisset, C., Standfield, S., Piscitelli, D., Rayner, C. K., Deane, A. M., & Jones, K. L. (2015) · Diabetologia · doi:10.1007/s00125-015-3638-0 · Cited by 52
“We assessed the acute responses to GLP-1, and it is now recognised that the slowing of GE by exogenous GLP-1 is subject to tachyphylaxis with sustained exposure [43, 44].”
BackgroundWerner, U. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.06.003 · Cited by 47
Zhou, Y., Chen, M., Liu, L., & Chen, Z. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s348025 · Cited by 46
“There is evidence suggesting that GLP1-induced deceleration of gastric emptying can be subject to rapid tachyphylaxis at the level of vagal nervous activation.(23) These differences in gastric emptying appear to translate into the clinical setting.”
BackgroundMihai, B. M., Mihai, C., Cijevschi-Prelipcean, C., Grigorescu, E.-D., Dranga, M., Drug, V., Sporea, I., & Lăcătușu, C. M. (2018) · Journal of Diabetes Research · doi:10.1155/2018/1736959 · Cited by 46
“The mechanism causing the difference between the evolution of GLP-1 effects over time is not known [59, 60].”
BackgroundCho, Y. M., Wideman, R. D., & Kieffer, T. J. (2013) · Endocrinology and Metabolism · doi:10.3803/enm.2013.28.4.262 · Cited by 44
The effects of sitagliptin on gastric emptying in healthy humans – a randomised, controlled study
Stevens, J. E., Horowitz, M., Deacon, C. F., Nauck, M., Rayner, C. K., & Jones, K. L. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05198.x · Cited by 45
Self-citationDiabetic Gastroparesis and Glycaemic Control
Jalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1281-8 · Cited by 47
Reiner, J., Berlin, P., Held, J., Thiery, J., Skarbaliene, J., Griffin, J., Russell, W., Eriksson, P., Berner‐Hansen, M., Ehlers, L., et al. (2022) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.2286 · Cited by 43
Chang, M. G., Ripoll, J. G., Lopez, E., Krishnan, K., & Bittner, E. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216336 · Cited by 43
“…doses of medications may result in a significant slowing of gastric emptying compared to lower dosing of medications using indirect measurements of gastric emptying, and that the duration of GLP-1 RA use may play a role given studies suggesting tachyphylaxis after prolonged GLP-1 RA use [63–66].”
BackgroundMetabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
Tanday, N., Flatt, P. R., & Irwin, N. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15485 · Cited by 41
Pharmacotherapy for the treatment of obesity
Sweeting, A., HOCKING, S. L., & Markovic, T. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.005 · Cited by 55
Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
Petersen, B., & Christensen (2013) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s45379 · Cited by 42
O'Harte, F. P. M., Parthsarathy, V., Hogg, C., & Flatt, P. R. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202350 · Cited by 44
Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist
Young, M. A., Wald, J. A., Matthews, J. E., Scott, R., Hodge, R. J., Zhi, H., & Reinhardt, R. R. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2836 · Cited by 41
Frandsen, C. S., Dejgaard, T. F., Andersen, H. U., Holst, J. J., Hartmann, B., Thorsteinsson, B., & Madsbad, S. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12830 · Cited by 40
“The apparent discrepancy between these findings may be explained by rapid tachyphylaxis of the GLP-1-induced deceleration of GE during prolonged exogenous administration of both native GLP-1 and long-acting GLP-1RA, as indicated in previous studies.(16,29,33) Additionally, it is generally recognized that the GE rate d…”
BackgroundSelf-citationInsights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
“However, this mechanism may only be relevant for short acting GLP-1RAs, where the delay in gastric emptying is seemingly not subjected to tachyphylaxis [137,138].”
BackgroundKim, H. S., & Jung, C. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189936 · Cited by 45
“GLP-1 has also been demonstrated to have pleiotropic effects, such as lowering hunger and food intake, as well as slowing stomach emptying and small bowel movement [20,21].”
BackgroundTreatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121808 · Cited by 38
“preprandial hyperglycemia via the stimulation of insulin secretion, inhibition of glucagon and not the slowing of gastric emptying, as this process undergoes tachyphylaxis.[6,110,111] In contrast, the clinical effects of the”
BackgroundAndreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14500 · Cited by 38
“In contrast, longacting GLP-1RAs are associated with tachyphylaxis of the effect on gastric emptying resulting in a modest effect of these compounds on postprandial glucose levels.(23) However, long-acting GLP-1RAs have a more pronounced effect on fasting plasma glucose levels and HbA1c reductions.”
BackgroundMovahednasab, M., Dianat‐Moghadam, H., Khodadad, S., Nedaeinia, R., Safabakhsh, S., Ferns, G. A., & Salehi, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01623-w · Cited by 47
Trahair, L. G., Horowitz, M., Hausken, T., Feinle-Bisset, C., Rayner, C. K., & Jones, K. L. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2475 · Cited by 37
“The slowing of GE by exogenous GLP-1 is subject to tachyphylaxis with sustained exposure (17).”
BackgroundBolli, G. B., & Owens, D. R. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12253 · Cited by 36
“The greater effect of exenatide versus liraglutide on PPG control has been interpreted as exenatide possessing a greater inhibitory effect on gastric emptying due to its short duration of action, which is in contrast to that of the longer-acting liraglutide [37].”
ResultPerioperative management of patients on glucagon-like peptide-1 receptor agonists
Mizubuti, G. B., Ho, A. M. ‐., da Silva, L. M., & Phelan, R. (2024) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001348 · Cited by 44
Knudsen, L. B., Secher, A., Hecksher‐Sørensen, J., & Pyke, C. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12463 · Cited by 36
“Figure 2 | Distribution of liraglutide(594) or exendin(9-39)(594) in the pancreas and brain.”
BackgroundInfluentialHyperglycemia Potentiates the Slowing of Gastric Emptying Induced by Exogenous GLP-1
Plummer, M. P., Jones, K. L., Cousins, C. E., Trahair, L. G., Meier, J. J., Chapman, M. J., Horowitz, M., & Deane, A. M. (2015) · Diabetes Care · doi:10.2337/dc14-3091 · Cited by 36
“It should also be recognized that with prolonged GLP-1 receptor stimulation the slowing of gastric emptying is attenuated but not abolished (31,33,34).”
BackgroundSelf-citationShah, V. N., Peters, A. L., Umpierrez, G. E., Sherr, J. L., Akturk, H. K., Aleppo, G., Bally, L., Cengiz, E., Cinar, A., Dungan, K., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241291512 · Cited by 36
“15 The pharmacologically administered GLP-1RAs affect central nervous system satiety pathways by acting on vagal afferent neurons and by engaging GLP-1 receptors located in the central nervous system that are not protected by the blood-brain barrier.”
Hinshaw, L., Schiavon, M., Mallad, A., Man, C. D., Basu, R., Bharucha, A. E., Cobelli, C., Carter, R. E., Basu, A., & Kudva, Y. C. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00199.2014 · Cited by 35
The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus
Christensen, M., Miossec, P., Larsen, B. D., Werner, U., & Knop, F. K. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.942638 · Cited by 34
le Roux, C. W., Hankosky, E. R., Wang, D., Malik, R., Yu, M., Hickey, A., Kan, H., Bunck, M. C., Stefanski, A., Garcia‐Perez, L., et al. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15148 · Cited by 36
CNS-targeting pharmacological interventions for the metabolic syndrome
Stemmer, K., Müller, T. D., DiMarchi, R. D., Pfluger, P. T., & Tschöp, M. H. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129195 · Cited by 36
“In contrast, long-acting GLP-1R agonists exert stronger effects on fasting glucose levels by causing prolonged stimulation of insulin secretion, but the effects on gastric emptying are subject to rapid tachyphylaxis (121).”
BackgroundGlucagon‐like peptide‐1 receptor agonists and the appropriate measurement of gastric emptying
Horowitz, M., Rayner, C. K., Marathe, C. S., Wu, T., & Jones, K. L. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14166 · Cited by 32
“However, in both studies, after continuous administration, gastric emptying was still slowed substantially by GLP-1.(12,13) Recent studies, using scintigraphy, have established that the ‘long-acting’ GLP-1RAs, exenatide once-weekly(11) and liraglutide,(14) do slow emptying with chronic administration, albeit probably…”
BackgroundÅhrén, B., Gautier, J., Berria, R., Stager, W., Aronson, R., & Bailey, C. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12290 · Cited by 33
“Efficacy differences in the slowing of gastric emptying of short- and long-acting GLP-1 receptor agonists may reflect a ‘tachyphylaxis’ effect, whereby continuous stimulation of the GLP-1 receptor leads to an attenuation of initial efficacy [16].”
BackgroundNgabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Chalmer, T., Almdal, T. P., Vilsbøll, T., & Knop, F. K. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.975205 · Cited by 31
“Interestingly, native GLP-1 has an inhibiting effect on gastric emptying, which seems to be associated with a certain degree of tachyphylaxis, which is more pronounced upon continuous administration compared to intermittent administration [23,24].”
BackgroundHypoglycaemia and gastric emptying
Marathe, C. S., Marathe, J. A., Rayner, C. K., Kar, P., Jones, K. L., & Horowitz, M. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13570 · Cited by 32
“Short-acting agents such as exenatide twice daily and lixisenatide diminish postprandial glycaemic excursions rather than fasting/preprandial glucose, primarily by slow- ing gastric emptying, while longer-acting drugs such as exenatide once weekly and liraglutide act chiefly to lower fasting/preprandial glycaemia by s…”
BackgroundRenner, S., Blutke, A., Streckel, E., Wanke, R., & Wolf, E. (2015) · The Journal of Pathology · doi:10.1002/path.4655 · Cited by 36
“This effect is known to exist also in other species, but is not as long-lasting in humans [126,127] as in pigs.”
BackgroundClinical Pharmacokinetics and Pharmacodynamics of Albiglutide
Brønden, A., Knop, F. K., & Christensen, M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0499-8 · Cited by 33
“Acute activation of the GLP-1 receptor has a delaying effect on gastric emptying, but continuous activation of this receptor induces tachyphylaxis to this effect [23, 24].”
BackgroundBlonde, L., Anderson, J. E., Chava, P., & Dendy, J. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1541790 · Cited by 33
Delayed Gastric Emptying with Perioperative Use of Glucagon-like Peptide-1 Receptor Agonists
Raven, L. M., Stoita, A., Feller, R. B., Brown, C., & Greenfield, J. R. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.07.016 · Cited by 30
Ohlsson, L., Alsalim, W., Carr, R. D., Tura, A., Pacini, G., Mari, A., & Åhrén, B. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12062 · Cited by 31
“It should be emphasized, however, that when comparing different studies on gastric emptying after incretinbased therapy, the length of treatment may be critical, as a longer duration of therapy might elicit tachyphylaxia of the effect of GLP-1 to delay gastric emptying, as evident by a recent study showing that only 4…”
ResultMiller, A., Deane, A., Plummer, M., Cousins, C. E., Chapple, L., Horowitz, M., & Chapman, M. (2017) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)00742-1 · Cited by 17
Chen, C.-Y., Rasmussen, H., Kamil, A., Du, P., & Blumberg, J. B. (2017) · Nutrients · doi:10.3390/nu9020130 · Cited by 32
Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population
Buckley, A., Suliman, S., Allum, M., Mohammed, N., Lessan, N., le Roux, C. W., & Suliman, M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15680 · Cited by 29
“15 Our data provide real-world evidence that switching to tir-zepatide from other GLP-RAs resulted in further improvements in HbA1c and weight.”
Jiang, Y., Zhu, H., & Gong, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16106 · Cited by 36
“58,59 Considering the inconsistency of the current findings, high-quality studies are still needed to validate the effect of delaying gastric emptying on the weight loss induced by GLP-1 agonist.”
van Ruiten, C. C., Veltman, D. J., Schrantee, A., van Bloemendaal, L., Barkhof, F., Kramer, M. H. H., Nieuwdorp, M., & IJzerman, R. G. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac043 · Cited by 38
Takahashi, Y., Nomoto, H., Yokoyama, H., Takano, Y., Nagai, S., Tsuzuki, A., Cho, K. Y., Miya, A., Kameda, H., Takeuchi, J., et al. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14998 · Cited by 29
“Among them, the effects on body weight control via inhibiting gastric peristalsis and reducing appetite are important components of these drugs.(8,9) Recent clinical trials illustrated that these drugs have beneficial effects on cardiovascular and renal outcomes.”
BackgroundChowdhury, S., Reeds, D. N., Crimmins, D. L., Patterson, B. W., Laciny, E., Wang, S., Tran, H. D., Griest, T. A., Rometo, D. A., Dunai, J., et al. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00383.2013 · Cited by 29
Maselli, D. B., Lee, D., Bi, D., Jirapinyo, P., Thompson, C. C., Donnangelo, L. L., & McGowan, C. E. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07278-2 · Cited by 28
Thong, K. Y., Gupta, P. S., Blann, A. D., & Ryder, R. E. J. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.009 · Cited by 29
“The side effects of GLP-1 receptor agonists also tend to improve with longer duration of treatment, possibly due to the development of tachyphylaxis [4].”
BackgroundWan, J., Ferrari, C., & Tadros, M. S. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15010014 · Cited by 34
“The delay in gastric emptying and peaks of the GLP-1 effect with short-acting formulations have been hypothesized as causative agents for the pervasiveness of nausea [48,49].”
BackgroundGastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome
Αλεξιάδου, Κ., & Tan, T. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01309-9 · Cited by 27
Stevens, J. E., Buttfield, M., Wu, T., Hatzinikolas, S., Pham, H., Lange, K. M., Rayner, C. K., Horowitz, M., & Jones, K. L. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13864 · Cited by 29
“While both exogenous(5) and endogenous(6) GLP-1 slow GE in healthy individuals, the effect of exogenous GLP-1 is attenuated markedly with continuous, as opposed to acute, or intermittent, exposure.(7,8) Accordingly, “short-acting” GLP1RAs have a major, and sustained, ability to slow GE.”
BackgroundGLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action
Burcelin, R., Gourdy, P., & Dalle, S. (2014) · Physiology · doi:10.1152/physiol.00009.2013 · Cited by 26
Goldenberg, R., & Berard, L. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1372118 · Cited by 27
Guan, H.-P., & Xiong, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1043828 · Cited by 31
“Although a rapid tachyphylaxis of GLP-1-induced deceleration of gastric emptying had been reported in humans (Nauck et al., 2011), tachyphylaxis has not been observed for either GLP-1RAs or GPR40 agonists after chronic treatments in preclinical and clinical studies (Burant et al.”
BackgroundPharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus
Forst, T., & Pfützner, A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.838559 · Cited by 25
“In contrast to long-acting agents, the effects of delayed gastric emptying with short-acting agonists do not appear to be subject to tachyphylaxis [70].”
BackgroundPai, S., Nimma, S., Beam, W. B., VanderWielen, B. A., Kalagara, H. K. P., Bettini, L. M., Yu, S., Sharpe, E. E., Harbell, M. W., & Collaborators, M. (. A. G. I. C. (2025) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000007764 · Cited by 39
Becker, R. H. A., Stechl, J., Msihid, J., & Kapitza, C. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12278 · Cited by 25
O’Malley, D. (2018) · Experimental Physiology · doi:10.1113/ep087443 · Cited by 30
Chronic Subcutaneous Brain Natriuretic Peptide Therapy in Asymptomatic Systolic Heart Failure
McKie, P. M., Schirger, J. A., Benike, S. L., Harstad, L. K., Slusser, J. P., Hodge, D. O., Redfield, M. M., Burnett, J. C. J., & Chen, H. H. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.468 · Cited by 27
Meier, J. J., Menge, B. A., Schenker, N., Erdmann, S., Kahle‐Stephan, M., Schliess, F., Kapitza, C., & Nauck, M. A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13935 · Cited by 24
Self-citationRomeo, G. R., Lee, J., Mulla, C. M., Noh, Y., Holden, C., & Lee, B.-C. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa094 · Cited by 31
Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide
Voukali, M., Kastrinelli, I., Stragalinou, S., Tasiopoulou, D., Paraskevopoulou, P., Katsilambros, N., Kokkinos, A., Tentolouris, N., & Ioannidis, I. (2014) · Journal of Diabetes Research · doi:10.1155/2014/304032 · Cited by 24
Ghazanfar, H., Javed, N., Qasim, A., Sosa, F., Altaf, F., Khan, S., Mahasamudram, J., Jyala, A., Kandhi, S. D., Shin, D., et al. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i26.3221 · Cited by 23
“None of the patients in the study required a repeat EGD due to 2 poor visualization[13].”
Muzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy
Khoo, B. C. E., & Tan, T. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0119 · Cited by 23
Neuromedin U inhibits food intake partly by inhibiting gastric emptying
Dalbøge, L. S., Pedersen, S. L., Secher, T., Holst, B., Vrang, N., & Jelsing, J. (2015) · Peptides · doi:10.1016/j.peptides.2015.04.010 · Cited by 25
Jones, B. J., Sands, C. J., Αλεξιάδου, Κ., MINNION, J. S., Tharakan, G., Behary, P., Ahmed, A., Purkayastha, S., Lewis, M. R., Bloom, S. R., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab608 · Cited by 21
“The potential for GLP-1R tachyphylaxis to influence metabolic responses (53,54) should”
BackgroundSuccessful Treatment of Reactive Hypoglycemia Secondary to Late Dumping Syndrome Using Miglitol
Fujita, Y., Tamada, D., Kozawa, J., Kobayashi, Y., Sasaki, S., Kitamura, T., Yasuda, T., Maeda, N., Otsuki, M., Okita, K., et al. (2012) · Internal Medicine · doi:10.2169/internalmedicine.51.8171 · Cited by 22
“GLP-1 has a physiological effect of inhibiting gastrointestinal motility, including the slowing of gastric emptying (25, 26).”
BackgroundWu, T., Rayner, C. K., & Horowitz, M. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0164 · Cited by 24
Raven, L. M., Brown, C., & Greenfield, J. R. (2024) · Medical Journal of Australia · doi:10.5694/mja2.52170 · Cited by 21
Gut-Based Strategies to Reduce Postprandial Glycaemia in Type 2 Diabetes
Kamruzzaman, M., Horowitz, M., Jones, K. L., & Marathe, C. S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.661877 · Cited by 24
Metadata
- Authors
- Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J.
- Affiliations
- Diabeteszentrum Bad Lauterberg (DE)
- Conservative Emergency Room, Klinikum Krefeld, Krefeld, Germany
- University of Copenhagen (DK)
- St. Josef-Hospital (DE)
- Corresponding author
- Nauck, Michael A.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-04-23
- Volume
- 60
- Issue
- 5
- Pages
- 1561-1565
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3292331
- OpenAlex
- W2163229244
- Cited by
- 392
- References
- 37
- Citations by year
- 2026: 35 · 2025: 32 · 2024: 38 · 2023: 23 · 2022: 18 · 2021: 22 · 2020: 21 · 2019: 23 · 2018: 20 · 2017: 17 · 2016: 24 · 2015: 26 · 2014: 33 · 2013: 42 · 2012: 11
- FWCI
- 24.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucagon-like peptide-1, tachyphylaxis, gastric emptying, postprandial glucose control, vagal activation, pancreatic polypeptide, insulin secretion, glucagon, C-peptide, mixed meal
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Gastric Emptying, Glucagon, Humans, Male, Tachyphylaxis, Postprandial Period, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.